The protective potential of killed Leishmania major (ALM) along with BCG was evaluated against L. donovani in Indian langur monkeys in single and triple dose schedules. A delayed protection was observed in monkeys after a single dose schedule of ALM (3 mg)+BCG (3 mg) given intradermally 2 months before intravenous challenge with L. donovani. Triple dose schedule each of 1 mg ALM + 1 mg BCG was more effective. The status remained unchanged until the end of the experiment (approximately 8 months). The study indicates that a combination of ALM + BCG may be a good candidate vaccine for exploiting against human Kala-azar.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1017/s0031182097002175 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of Cellular Immune Responses in Dogs Immunized with Alum-Precipitated Autoclaved along with BCG and Imiquimod.
Iran J Parasitol
January 2021
Department of Immunology, Pasteur Institute of Iran, Tehran, Iran.
Background: We aimed to investigate the potential effects of BCG and imiquimod on improvement of current experimental vaccine against dogs in an endemic area of Zoonotic visceral leishmaniasis (ZVL) in Iran.
Methods: During 2012 till 2014, seven mixed-breed shepherd dogs with no anti- antibodies and no response to Leishmanin reagent were immunized with 2 doses of alum-precipitated autoclaved (Alum-AML) while BCG and imiquimod (for skin pre-treatment) were used as adjuvants. The productions of a few characteristic cytokines of T-helper immune responses and the development of delayed-type hypersensitivity (DTH) of the immunized animals were then evaluated, up to 300 days.
Therapeutic Modalities in Post Kala-azar Dermal Leishmaniasis: A Systematic Review of the Effectiveness and Safety of the Treatment Options.
Indian J Dermatol
January 2021
Department of Dermatology, Bankura Sammilani Medical College, Bankura, West Bengal, India.
Post-kala-azar dermal Leishmaniasis (PKDL) is one of the important neglected tropical diseases, which has a tremendous epidemiological significance, being the reservoir of kala-azar. Relapse and resistance to treatment along with the lack of a drug of choice and consensus treatment guideline pose a significant problem in the management of PKDL. The aim of this article was to review the available therapeutic options for PKDL, with special emphasis on their pharmaco-dynamics, pharmaco-kinetics, effectiveness, safety, tolerability, and cost factor.
View Article and Find Full Text PDFThe Strange Case of BCG and COVID-19: The Verdict Is Still up in the Air.
Vaccines (Basel)
October 2020
Public Health Research Institute at New Jersey Medical School, Rutgers University, Newark, NJ 07103, USA.
COVID-19, caused by a novel coronavirus, SARS-CoV-2, contributes significantly to the morbidity and mortality in humans worldwide. In the absence of specific vaccines or therapeutics available, COVID-19 cases are managed empirically with the passive immunity approach and repurposing of drugs used for other conditions. Recently, a concept that bacilli Calmette-Guerin (BCG) vaccination could confer protection against COVID-19 has emerged.
View Article and Find Full Text PDFGuidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Autophagy
October 2016
kb Emory University, School of Medicine, Department of Microbiology and Immunology , Atlanta , GA , USA.
Double-Blind Randomized Efficacy Field Trial of Alum Precipitated Autoclaved Leishmania major (Alum-ALM) Vaccine Mixed With BCG Plus Imiquimod Vs. Placebo Control Group.
Iran J Parasitol
December 2015
Meshkin-Shahr Research station, School of Public Health, Tehran University of Medical Sciences, Iran.
Background: Canine visceral leishmaniasis (CVL) is not only an emerging veterinary concern but also a public health threat in endemic areas. The aim of this study was to assess the efficacy, immunogenicity and safety of two doses of aluminum hydroxide (alum) precipitated Leishmania major (Alum-ALM) mixed with BCG plus imiquimod against CVL.
Methods: A total of 560 ownership dogs were serologically tested and 234 healthy dogs with no clinical signs of CVL, no anti-Leishmania antibodies and negative leishmanin skin test were selected and double-blind randomly injected intradermally either with 0.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!